Figure 2. Proportion of people starting HAART at CD4 counts 101 – 200 cells/mm3 who failed first-line therapy and time to treatment failure (days) comparing 2NRTIs+NNRTI with 2NRTIs+PIboosted first-line regimens.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.